Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin

McCurdy, Lewis; Milstone, Aaron P.; Dummer, Stephen

doi:10.1016/s1053-2498(02)00569-7

Cited by 100 publications

(118 citation statements)

References 24 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…Ribavirin has been employed in the treatment of RSV, PIV, and AdV infections [91][92][93], although its use is proven only in RSV-related disease, whereas neuraminidase inhibitors were effective in controlled trials in adults and children with IVs [94]. Although no randomized controlled trials of therapy for AdV infection have been published, cidofovir given i.v.…”

Section: Respiratory Virusesmentioning

confidence: 99%

Monitoring and managing viral infections in pediatric renal transplant recipients

Comoli

Ginevri

2011

Pediatr Nephrol

View full text Add to dashboard Cite

Viral infections remain a significant cause of morbidity and mortality following renal transplantation. The pediatric cohort is at high risk of developing virus-related complications due to immunological naiveté and the increased alloreactivity risk that requires maintaining a heavily immunosuppressive environment. Although cytomegalovirus is the most common opportunistic pathogen seen in transplant recipients, numerous other viruses may affect clinical outcome. Recent technological advances and novel antiviral therapy have allowed implementation of viral and immunological monitoring protocols and adoption of prophylactic or preemptive treatment approaches in high-risk groups. These strategies have led to improved viral infection management in the immunocompromised host, with significant impact on outcome. We review the major viral infections seen following kidney transplantation and discuss strategies for preventing and managing these pathogens.

show abstract

Section: Respiratory Virusesmentioning

confidence: 99%

Monitoring and managing viral infections in pediatric renal transplant recipients

Comoli

Ginevri

2011

Pediatr Nephrol

View full text Add to dashboard Cite

show abstract

“…8,14,19,20 This is of significance since prior studies demonstrating allograft stability after paramyxovirus infection have primarily utilized inhaled or intravenous ribavirin formulations that are more expensive and more cumbersome modes of delivery. 14 No severe grade 3 infections were seen in our patients, which recapitulates the findings of prior work.…”

Section: Discussionmentioning

confidence: 99%

Clinical Outcomes of Paramyxovirus Infections in Lung Transplant Recipients Treated With Oral Ribavirin: A Two-Center Case Series

Garcia

Sharma²,

Johnson³

et al. 2019

Exp Clin Transplant

View full text Add to dashboard Cite

show abstract

“…Mortality attributable to LRD with RSV in this population has been reported from 10 to 20 % [57,60]. A prospective study identified only 2 of 51 adult liver transplant recipients with RSV, and both had only mild upper respiratory symptoms [65].…”

Section: Sot Clinical Disease and Epidemiologymentioning

confidence: 91%

“…The cumulative incidence of RSV infection in lung transplant over 5-7 years has varied from 8 to 21 % in several retrospective series, with an annual incidence describe of 2-16 % [57][58][59][60][61][62][63][64]. Mortality attributable to LRD with RSV in this population has been reported from 10 to 20 % [57,60].…”

Section: Sot Clinical Disease and Epidemiologymentioning

confidence: 99%

Respiratory Syncytial Virus in Hematopoietic Stem Cell Transplantation and Solid-Organ Transplantation

Neemann

Freifeld

2015

Curr Infect Dis Rep

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV), one of the most common causes of respiratory infections in immunocompetent individuals, can cause significant pulmonary morbidity and mortality in hematopoietic stem cell (HSCT) and less often in solid-organ transplant recipients. Early diagnosis and medical intervention prior to the progression from upper to lower respiratory tract viral involvement is essential to positively affect the clinical course. The greatest risk of disease progression from upper to lower respiratory tract disease is during the early posttransplant period for HSCT recipients, with lymphopenia being an important risk factor. Polymerase chain reaction has become the preferred method for rapidly diagnosing infection in this population because of higher sensitivity compared to traditional viral culture and direct viral antigen methods. Despite the lack of prospective randomized trials, retrospective pooled analyses have suggested that systemically delivered ribavirin (either aerosolized, oral, or IV; with or without immunomodulator therapy) can decrease the risk of progression of disease. Additionally, there are a number of clinical trials currently in process to evaluate several new agents that target RSV in the high-risk HSCT patient population.

show abstract

Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin

Cited by 100 publications

References 24 publications

Monitoring and managing viral infections in pediatric renal transplant recipients

Monitoring and managing viral infections in pediatric renal transplant recipients

Clinical Outcomes of Paramyxovirus Infections in Lung Transplant Recipients Treated With Oral Ribavirin: A Two-Center Case Series

Respiratory Syncytial Virus in Hematopoietic Stem Cell Transplantation and Solid-Organ Transplantation

Contact Info

Product

Resources

About